BW Healthcare World - 28 April 2026
The India–New Zealand Free Trade Agreement (FTA), signed in April 2026 after negotiations resumed in March 2025, is being positioned as one of India’s quickest major trade agreements in recent years. The pact grants 100per cent duty-free access to 8,284 Indian export tariff lines into New Zealand from the day it comes into force, while also including a USD 20 billion investment facilitation commitment aimed at strengthening long-term economic ties.
According to Pavan Choudary, Chairman of the Medical Technology Association of India (MTaI), the speed of the agreement signals more than trade efficiency, reflecting deeper strategic coordination between the two countries. For Indian industry, the immediate benefit lies in broad tariff elimination across sectors including pharmaceuticals, medical devices, diagnostics and engineering products.
Faster access for pharma and MedTech
A major component of the agreement is a dedicated pharmaceuticals and medical devices annex intended to reduce regulatory barriers and accelerate market entry for Indian healthcare products in New Zealand.
Under this framework, New Zealand will accept Good Manufacturing Practice (GMP) and Good Clinical Practice (GCP) inspection reports from the US FDA, European Medicines Agency (EMA), and the UK’s MHRA. This is expected to lower duplicate compliance requirements and reduce inspection-related delays for Indian exporters.
For Indian MedTech manufacturers, the arrangement could simplify approvals for products such as diagnostics, implants, imaging systems and digital health technologies, potentially improving access to New Zealand’s hospitals and healthcare providers as the country expands its supplier base.
Health services, wellness and AYUSH gain entry routes
The FTA also extends beyond product exports. A separate annex on health services and traditional medicine creates formal channels for medical-value travel, telemedicine and digital-health partnerships.
It additionally incorporates evidence-based AYUSH systems—including Ayurveda, Yoga, Unani, Siddha and Homeopathy within the broader health-services framework, providing Indian wellness and traditional medicine companies a structured route into New Zealand.
This broadens India’s positioning from a manufacturer of medicines and devices to a wider healthcare and wellness services provider. Given that people of Indian origin make up about 5per cent of New Zealand’s population, industry observers expect sustained demand for culturally familiar healthcare and wellness offerings.
CDSCO recognition remains a strategic gap
Despite the regulatory gains, Choudary has identified one major limitation: India’s Central Drugs Standard Control Organisation (CDSCO) is not currently included in the regulatory recognition structure.
He argued that as India’s pharmaceutical and medical technology sectors strengthen their quality standards, CDSCO’s inclusion in future bilateral recognition systems is commercially important. Without such recognition, Indian manufacturers could still face added scrutiny compared with competitors whose domestic regulators are already accepted.
Industry stakeholders are expected to push for CDSCO’s inclusion during future review rounds of the India–New Zealand FTA and in other upcoming bilateral trade negotiations, as this could further reduce approval timelines and strengthen India’s role as a global regulatory partner.
Mobility provisions strengthen workforce links
The agreement also includes provisions covering post-study work rights and skilled professional mobility, potentially benefiting Indian graduates and professionals entering New Zealand’s workforce.
This is expected to support healthcare-related sectors such as biomedical engineering, digital health and clinical support, where New Zealand continues to expand infrastructure and workforce capacity.
With an Indian-origin community of more than 300,000 already established in New Zealand, the agreement builds on existing commercial and social ties rather than creating entirely new ones.
A broader strategic platform
For India’s healthcare, pharmaceutical and MedTech industries, the FTA represents more than tariff reduction. It creates a framework for expanded exports, regulatory alignment, healthcare services growth and talent mobility.
As implementation begins, industry attention is likely to focus on whether CDSCO gains future recognition and whether this agreement becomes a model for India’s future trade partnerships with other developed economies.
